The management of primary sclerosing cholangitis.
Primary sclerosing cholangitis is a chronic cholestatic liver disease characterized by a progressive, obliterating fibrosis of the intrahepatic and extrahepatic bile ducts. The pathogenesis of PSC is unknown, but it is thought to be an immune-mediated disease. Although the role of cupruretics, immun...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
1998
|
| _version_ | 1797105889353662464 |
|---|---|
| author | Mitchell, SA Chapman, R |
| author_facet | Mitchell, SA Chapman, R |
| author_sort | Mitchell, SA |
| collection | OXFORD |
| description | Primary sclerosing cholangitis is a chronic cholestatic liver disease characterized by a progressive, obliterating fibrosis of the intrahepatic and extrahepatic bile ducts. The pathogenesis of PSC is unknown, but it is thought to be an immune-mediated disease. Although the role of cupruretics, immunosuppressants (corticosteroids, azathioprine, tacrolimus, methotrexate), antifibrogenic agents, and ursodeoxycholic acid in the treatment of primary sclerosing cholangitis is reviewed, none of these agents has been shown to retard or reverse the rate of disease progression. Of these therapies, ursodeoxycholic acid at high doses looks the most promising, but large trials are needed to establish whether treatment with high-dose ursodeoxycholic acid influences the morbidity and mortality associated with primary sclerosing cholangitis. |
| first_indexed | 2024-03-07T06:53:48Z |
| format | Journal article |
| id | oxford-uuid:fd7025a0-65ad-4736-87d4-b6c10ce15511 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:53:48Z |
| publishDate | 1998 |
| record_format | dspace |
| spelling | oxford-uuid:fd7025a0-65ad-4736-87d4-b6c10ce155112022-03-27T13:28:50ZThe management of primary sclerosing cholangitis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:fd7025a0-65ad-4736-87d4-b6c10ce15511EnglishSymplectic Elements at Oxford1998Mitchell, SAChapman, RPrimary sclerosing cholangitis is a chronic cholestatic liver disease characterized by a progressive, obliterating fibrosis of the intrahepatic and extrahepatic bile ducts. The pathogenesis of PSC is unknown, but it is thought to be an immune-mediated disease. Although the role of cupruretics, immunosuppressants (corticosteroids, azathioprine, tacrolimus, methotrexate), antifibrogenic agents, and ursodeoxycholic acid in the treatment of primary sclerosing cholangitis is reviewed, none of these agents has been shown to retard or reverse the rate of disease progression. Of these therapies, ursodeoxycholic acid at high doses looks the most promising, but large trials are needed to establish whether treatment with high-dose ursodeoxycholic acid influences the morbidity and mortality associated with primary sclerosing cholangitis. |
| spellingShingle | Mitchell, SA Chapman, R The management of primary sclerosing cholangitis. |
| title | The management of primary sclerosing cholangitis. |
| title_full | The management of primary sclerosing cholangitis. |
| title_fullStr | The management of primary sclerosing cholangitis. |
| title_full_unstemmed | The management of primary sclerosing cholangitis. |
| title_short | The management of primary sclerosing cholangitis. |
| title_sort | management of primary sclerosing cholangitis |
| work_keys_str_mv | AT mitchellsa themanagementofprimarysclerosingcholangitis AT chapmanr themanagementofprimarysclerosingcholangitis AT mitchellsa managementofprimarysclerosingcholangitis AT chapmanr managementofprimarysclerosingcholangitis |